Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 234, Issue 8, Pages 12581-12594Publisher
WILEY
DOI: 10.1002/jcp.28134
Keywords
cardiovascular disease; coenzyme Q10; l-carnitine; lipoprotein(a); natural products; nutraceuticals; resveratrol
Categories
Funding
- Amgen
- Angelini
- Boehringer Ingelheim
- Galenica
- MSD
- Novartis
- Novo Nordisk
- Sanofi
- WinMedica
Ask authors/readers for more resources
Elevated plasma lipoprotein(a) (Lp(a)) levels are associated with an increased risk of cardiovascular disease (CVD). Hitherto, niacin has been the drug of choice to reduce elevated Lp(a) levels in hyperlipidemic patients but its efficacy in reducing CVD outcomes has been seriously questioned by recent clinical trials. Additional drugs may reduce to some extent plasma Lp(a) levels but the lack of a specific therapeutic indication for Lp(a)-lowering limits profoundly reduce their use. An attractive therapeutic option is natural products. In several preclinical and clinical studies as well as meta-analyses, natural products, including l-carnitine, coenzyme Q (10), and xuezhikang were shown to significantly decrease Lp(a) levels in patients with Lp(a) hyperlipoproteinemia. Other natural products, such as pectin, Ginkgo biloba, flaxseed, red wine, resveratrol and curcuminoids can also reduce elevated Lp(a) concentrations but to a lesser degree. In conclusion, aforementioned natural products may represent promising therapeutic agents for Lp(a) lowering.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available